EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2023-07-26

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

2023-06-30

EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”

2023-04-14

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

2023-04-11

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China

2023-03-08

Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance

2023-03-08

Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready

2023-02-23

2023-02-22

Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT